Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Cassava (SAVA) Posts Top-Line Data from AD Study on Simufilam

Published 09/22/2021, 10:30 PM
Updated 07/09/2023, 06:31 AM

Cassava Sciences (NASDAQ:SAVA), Inc. SAVA announced top-line data from an interim analysis of the ongoing study evaluating its drug candidate, simufilam, for treating patients with mild-to-moderate Alzheimer’s disease (“AD”).

Data from the study showed that the first 50 subjects who completed one year of open-label treatment with simufilam saw their cognition scores improve at an average of 3.2 points on Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog) from the baseline. The study is being funded by the National Institutes of Health.

68% of study subjects showed improvement on ADAS-Cog and an additional 20% of the subjects showed decline of less than five points on ADAS-Cog at 12 months of treatment.

Overall, treatment with simufilam was generally well-tolerated, with no serious adverse side effect observed through the 12-month interim analysis.

Shares of Cassava have skyrocketed 667% so far this year against the industry’s decrease of 12.5%.

Zacks Investment Research
Image Source: Zacks Investment Research

In August 2021, Cassava reached an agreement with the FDA on Special Protocol Assessments (“SPA”) for its phase III studies of simufilam for the treatment of AD. The SPAs underscore the company’s alignment with the FDA on key scientific, clinical and regulatory requirements of the phase III program of simufilam in AD. The company plans to initiate the studies in the fourth quarter of 2021.

Simufilam is a proprietary, small-molecule (oral) drug that restores the normal shape and function of altered filamin A, a scaffolding protein, in the brain.

Quite a few companies are striving hard to get their AD drugs approved. Eli Lilly LLY is developing donanemab, an investigational antibody therapy, for AD. Small biotech Annovis Bio, Inc. ANVS is also developing its pipeline candidate in mid-stage study for treating AD.

The FDA approval of Biogen’s BIIB AD drug, Aduhelm (aducanumab), has put the spotlight on this promising yet challenging space. In June 2021, Biogen and its partner Eisai won the FDA approval for Aduhelm as the first and only AD treatment, after a few setbacks.

Zacks Rank

Cassava currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.


More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.

Click here for the 4 trades >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Biogen Inc. (NASDAQ:BIIB): Free Stock Analysis Report

Eli Lilly and Company (NYSE:LLY): Free Stock Analysis Report

Cassava Sciences, Inc. (SAVA): Free Stock Analysis Report

Annovis Bio, Inc. (ANVS): Get Free Report

To read this article on Zacks.com click here.

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.